RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has again
been named as one of the TSX Venture Top 50 companies. 


The 2014 TSX Venture 50 is an annual ranking of strong performing companies
listed on the TSX Venture Exchange. The TSX Venture 50 includes the top 10
companies in five major industry sectors that have been identified as leaders in
Canada's public venture market. BioSyent is ranked on the list of ten leading
Technology and Life Sciences companies for the year. Companies are selected
based on four equally weighted criteria - return on investment, trading
activity, market capitalization growth, and analyst coverage. The results were
obtained from data to December 31, 2013.


BioSyent is the only TSX Venture Company ranked as a top performer in each of
2012, 2013, and 2014.


"With more than 2,100 companies listed on the TSX Venture Exchange, it is a
testament to the performance of our team to have BioSyent named for three
consecutive years as one of the TSX Venture Top 50 companies," said Rene
Goehrum, President and CEO of BioSyent Inc. "Our business has progressed
dramatically since we were named to the 2012 TSX Venture 50. Being named again
to the TSX Venture 50 is recognition by investors that we have an effective
strategy and that we have been consistently effective in executing that
strategy." 


For a direct market quote (15 minute delay) for the TSX Venture Exchange and
other company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the company had 13,626,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements.  Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. René C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024